Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Supernus Pharmaceuticals, Inc.

Market Cap 2.53B 2.2B 2.02B 1.9B 3.56B 239B 3.61B 24.03B 9.33B 117B 9.49B 9.29B 406B P/E 2026 *
101x
P/E 2027 * 30.7x
Enterprise Value 2.53B 2.2B 2.02B 1.9B 3.56B 239B 3.61B 24.03B 9.33B 117B 9.49B 9.29B 406B EV / Sales 2026 *
2.92x
EV / Sales 2027 * 2.48x
Free-Float
95.54%
Yield 2026 *
-
Yield 2027 * -
1 week-4.56%
Current month-5.63%
1 month-11.83%
3 months-13.20%
6 months-9.81%
Current year-12.31%
1 week 42.45
Extreme 42.45
45.89
1 month 42.45
Extreme 42.45
50
Current year 42.45
Extreme 42.45
59.68
1 year 30.83
Extreme 30.83
59.68
3 years 21.99
Extreme 21.99
59.68
5 years 21.99
Extreme 21.99
59.68
10 years 13.12
Extreme 13.12
61.25
Manager TitleAgeSince
Chief Executive Officer 64 2005-12-21
Director of Finance/CFO 67 2021-08-22
Compliance Officer 63 2011-12-31
Director TitleAgeSince
Director/Board Member 64 2005-12-21
Chairman 80 2016-08-09
Director/Board Member 80 2010-11-15
Date Insider Type Main position Quantity % Market Cap.
03-15Fiscal year

Chief Technology Officer

321,750 0.5738%
03-12Others

Founder

60,000 0.1070%
03-11Sell

Director

5,369 0.0096%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-4.56%+34.22%+29.05% 2.53B
+0.23%-3.48%+42.59%+5.60% 284B
+1.02%-3.44%+16.35%-19.76% 66.62B
-1.54%-4.07%+27.17%+96.03% 8.26B
+1.89%+4.68%-1.96%-11.45% 7.84B
+1.92%-1.63%-1.63%+5.36% 4.6B
+1.02%+3.13%-25.59%+41.73% 3.87B
+0.42%-0.78%-17.81%+4.86% 3.15B
-0.35%+3.98%+2.25%-27.01% 1.95B
-1.30%-3.79%-22.50%-26.51% 1.68B
Average +0.33%-1.13%+5.31%+9.79% 38.49B
Weighted average by Cap. +0.38%-3.50%+34.56%+3.01%

Financials

2026 *2027 *
Net sales 867M 754M 693M 652M 1.22B 81.97B 1.24B 8.24B 3.2B 40.18B 3.25B 3.19B 139B 1.02B 887M 815M 767M 1.44B 96.39B 1.45B 9.69B 3.76B 47.26B 3.83B 3.75B 164B
Net income 25.2M 21.91M 20.14M 18.95M 35.51M 2.38B 35.93M 239M 92.93M 1.17B 94.57M 92.55M 4.04B 82.76M 71.96M 66.15M 62.25M 117M 7.82B 118M 786M 305M 3.83B 311M 304M 13.28B
Net Debt - -
Logo Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is developing a range of CNS product candidates including new potential treatments for epilepsy, depression, ADHD, and other CNS disorders. Its products marketed in the United States include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC, ONAPGOTM (formerly known as SPN-830), and ZURZUVAE. Qelbree (viloxazine extended-release capsules) is a non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients 6 years and older.
Employees
778
Date Price Change Volume
26-06-17 43.58 $ 0.00% 541,838
26-06-16 43.58 $ -0.64% 720,139
26-06-15 43.86 $ -1.24% 902,284
26-06-12 44.41 $ -2.50% 825,356
26-06-11 45.55 $ +1.02% 478,366
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
43.58USD
Average target price
62.83USD
Spread / Average Target
+44.18%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SUPN Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!